Selected research
Market Outlook & Growth Opportunities
Global PD-L1 Inhibitors Market Outlook and Growth Opportunities 2026
Market perspective
The global PD-L1 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for PD-L1 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for PD-L1 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for PD-L1 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the PD-L1 Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the PD-L1 Inhibitors market include Merck KGaA, Roche and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global PD-L1 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of PD-L1 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents PD-L1 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-L1 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.
PD-L1 Inhibitors Segment by Company
Merck KGaA
Roche
AstraZeneca
PD-L1 Inhibitors Segment by Type
TECENTRIQ
Imfinzi
Bavencio
PD-L1 Inhibitors Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
PD-L1 Inhibitors Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global PD-L1 Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions PD-L1 Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify PD-L1 Inhibitors significant trends, drivers, influence factors in global and regions.
6. To analyze PD-L1 Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the PD-L1 Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-L1 Inhibitors industry.
Chapter 3: Detailed analysis of PD-L1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of PD-L1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of PD-L1 Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. PD-L1 Inhibitors Industry Trends
Table 2. PD-L1 Inhibitors Industry Drivers
Table 3. PD-L1 Inhibitors Industry Opportunities and Challenges
Table 4. PD-L1 Inhibitors Industry Restraints
Table 5. Global PD-L1 Inhibitors Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global PD-L1 Inhibitors Revenue Share by Company (2021-2026)
Table 7. Global PD-L1 Inhibitors Sales Volume by Company (K Units) & (2021-2026)
Table 8. Global PD-L1 Inhibitors Sales Volume Share by Company (2021-2026)
Table 9. Global PD-L1 Inhibitors Average Price (US$/Unit) of Company (2021-2026)
Table 10. Global PD-L1 Inhibitors Company Ranking, (2024-2026) & (USD Million)
Table 11. Global PD-L1 Inhibitors Key Company Manufacturing Base & Headquarters
Table 12. Global PD-L1 Inhibitors Company, Product Type & Application
Table 13. Global PD-L1 Inhibitors Company Establishment Date
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global PD-L1 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Significant Companies of TECENTRIQ
Table 18. Significant Companies of Imfinzi
Table 19. Significant Companies of Bavencio
Table 20. Global PD-L1 Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units)
Table 21. Global PD-L1 Inhibitors Sales Volume by Type (2021-2026) & (K Units)
Table 22. Global PD-L1 Inhibitors Sales Volume by Type (2027-2032) & (K Units)
Table 23. Global PD-L1 Inhibitors Sales Volume Share by Type (2021-2026)
Table 24. Global PD-L1 Inhibitors Sales Volume Share by Type (2027-2032)
Table 25. Global PD-L1 Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 26. Global PD-L1 Inhibitors Sales Value by Type (2021-2026) & (US$ Million)
Table 27. Global PD-L1 Inhibitors Sales Value by Type (2027-2032) & (US$ Million)
Table 28. Global PD-L1 Inhibitors Sales Value Share by Type (2021-2026)
Table 29. Global PD-L1 Inhibitors Sales Value Share by Type (2027-2032)
Table 30. Significant Companies of Retail Pharmacy
Table 31. Significant Companies of Hospital Pharmacy
Table 32. Significant Companies of Other
Table 33. Global PD-L1 Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units)
Table 34. Global PD-L1 Inhibitors Sales Volume by Application (2021-2026) & (K Units)
Table 35. Global PD-L1 Inhibitors Sales Volume by Application (2027-2032) & (K Units)
Table 36. Global PD-L1 Inhibitors Sales Volume Share by Application (2021-2026)
Table 37. Global PD-L1 Inhibitors Sales Volume Share by Application (2027-2032)
Table 38. Global PD-L1 Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 39. Global PD-L1 Inhibitors Sales Value by Application (2021-2026) & (US$ Million)
Table 40. Global PD-L1 Inhibitors Sales Value by Application (2027-2032) & (US$ Million)
Table 41. Global PD-L1 Inhibitors Sales Value Share by Application (2021-2026)
Table 42. Global PD-L1 Inhibitors Sales Value Share by Application (2027-2032)
Table 43. Global PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 44. Global PD-L1 Inhibitors Sales by Region (2021-2026) & (K Units)
Table 45. Global PD-L1 Inhibitors Sales Market Share by Region (2021-2026)
Table 46. Global PD-L1 Inhibitors Sales by Region (2027-2032) & (K Units)
Table 47. Global PD-L1 Inhibitors Sales Market Share by Region (2027-2032)
Table 48. Global PD-L1 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 49. Global PD-L1 Inhibitors Sales Value by Region (2021-2026) & (US$ Million)
Table 50. Global PD-L1 Inhibitors Sales Value Share by Region (2021-2026)
Table 51. Global PD-L1 Inhibitors Sales Value by Region (2027-2032) & (US$ Million)
Table 52. Global PD-L1 Inhibitors Sales Value Share by Region (2027-2032)
Table 53. Global PD-L1 Inhibitors Market Average Price (US$/Unit) by Region (2021-2026)
Table 54. Global PD-L1 Inhibitors Market Average Price (US$/Unit) by Region (2027-2032)
Table 55. Global PD-L1 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Table 56. Global PD-L1 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 57. Global PD-L1 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 58. Global PD-L1 Inhibitors Sales Market Share by Country (2021-2026)
Table 59. Global PD-L1 Inhibitors Sales by Country (2027-2032) & (K Units)
Table 60. Global PD-L1 Inhibitors Sales Market Share by Country (2027-2032)
Table 61. Global PD-L1 Inhibitors Sales Value by Country (2021-2026) & (US$ Million)
Table 62. Global PD-L1 Inhibitors Sales Value Market Share by Country (2021-2026)
Table 63. Global PD-L1 Inhibitors Sales Value by Country (2027-2032) & (US$ Million)
Table 64. Global PD-L1 Inhibitors Sales Value Market Share by Country (2027-2032)
Table 65. Merck KGaA Company Information
Table 66. Merck KGaA Business Overview
Table 67. Merck KGaA PD-L1 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 68. Merck KGaA PD-L1 Inhibitors Product Portfolio
Table 69. Merck KGaA Recent Development
Table 70. Roche Company Information
Table 71. Roche Business Overview
Table 72. Roche PD-L1 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 73. Roche PD-L1 Inhibitors Product Portfolio
Table 74. Roche Recent Development
Table 75. AstraZeneca Company Information
Table 76. AstraZeneca Business Overview
Table 77. AstraZeneca PD-L1 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. AstraZeneca PD-L1 Inhibitors Product Portfolio
Table 79. AstraZeneca Recent Development
Table 80. Key Raw Materials
Table 81. Raw Materials Key Suppliers
Table 82. PD-L1 Inhibitors Distributors List
Table 83. PD-L1 Inhibitors Customers List
Table 84. Research Programs/Design for This Report
Table 85. Authors List of This Report
Table 86. Secondary Sources
Table 87. Primary Sources
List of Figures
Figure 1. PD-L1 Inhibitors Product Image
Figure 2. Global PD-L1 Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million)
Figure 4. Global PD-L1 Inhibitors Sales (2021-2032) & (K Units)
Figure 5. Global PD-L1 Inhibitors Sales Average Price (US$/Unit) & (2021-2032)
Figure 6. Global PD-L1 Inhibitors Company Revenue Ranking in 2025 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 9. TECENTRIQ Image
Figure 10. Imfinzi Image
Figure 11. Bavencio Image
Figure 12. Global PD-L1 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 13. Global PD-L1 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032
Figure 14. Global PD-L1 Inhibitors Sales Volume Share by Type (2021-2032)
Figure 15. Global PD-L1 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 16. Global PD-L1 Inhibitors Sales Value Share 2021 VS 2025 VS 2032
Figure 17. Global PD-L1 Inhibitors Sales Value Share by Type (2021-2032)
Figure 18. Retail Pharmacy Image
Figure 19. Hospital Pharmacy Image
Figure 20. Other Image
Figure 21. Global PD-L1 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 22. Global PD-L1 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032
Figure 23. Global PD-L1 Inhibitors Sales Volume Share by Application (2021-2032)
Figure 24. Global PD-L1 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 25. Global PD-L1 Inhibitors Sales Value Share 2021 VS 2025 VS 2032
Figure 26. Global PD-L1 Inhibitors Sales Value Share by Application (2021-2032)
Figure 27. Global PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Figure 28. Global PD-L1 Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032
Figure 29. Global PD-L1 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 30. Global PD-L1 Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 31. North America PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million)
Figure 32. North America PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032
Figure 33. Europe PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million)
Figure 34. Europe PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032
Figure 35. Asia-Pacific PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million)
Figure 36. Asia-Pacific PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032
Figure 37. South America PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million)
Figure 38. South America PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032
Figure 39. Middle East & Africa PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million)
Figure 40. Middle East & Africa PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032
Figure 41. USA PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. USA PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. USA PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. Canada PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. Canada PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. Canada PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. Mexico PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. Mexico PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. Mexico PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Germany PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Germany PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Germany PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. France PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. France PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. France PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. U.K. PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. U.K. PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. U.K. PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Italy PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Italy PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Italy PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Spain PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Spain PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Spain PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. Russia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. Russia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. Russia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Netherlands PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Netherlands PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Netherlands PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. Nordic Countries PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. Nordic Countries PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. Nordic Countries PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. China PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. China PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. China PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Japan PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Japan PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Japan PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. South Korea PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. South Korea PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. South Korea PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. India PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. India PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. India PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Australia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Australia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Australia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Southeast Asia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Southeast Asia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Southeast Asia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Brazil PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Brazil PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Brazil PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Argentina PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Argentina PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Argentina PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Chile PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Chile PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Chile PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Colombia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Colombia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Colombia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. Peru PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. Peru PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. Peru PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Saudi Arabia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Saudi Arabia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Saudi Arabia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Israel PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Israel Arabia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Israel Arabia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. UAE PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. UAE PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. UAE PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. Turkey PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 117. Turkey PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 118. Turkey PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 119. Iran PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 120. Iran PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 121. Iran PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 122. Egypt PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 123. Egypt PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 124. Egypt PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 125. PD-L1 Inhibitors Value Chain
Figure 126. Manufacturing Cost Structure
Figure 127. PD-L1 Inhibitors Sales Mode & Process
Figure 128. Direct Comparison with Distribution Share
Figure 129. Distributors Profiles
Figure 130. Years Considered
Figure 131. Research Process
Figure 132. Key Executives Interviewed
Scope & coverage.
Types
- TECENTRIQ
- Imfinzi
- Bavencio
Applications
- Retail Pharmacy
- Hospital Pharmacy
- Other
Companies covered
- Merck KGaA
- Roche
- AstraZeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global PD-L1 Inhibitors Sales Value (2021-2032)
- 1.2.2 Global PD-L1 Inhibitors Sales Volume (2021-2032)
- 1.2.3 Global PD-L1 Inhibitors Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 PD-L1 Inhibitors Market Dynamics
- 2.1 PD-L1 Inhibitors Industry Trends
- 2.2 PD-L1 Inhibitors Industry Drivers
- 2.3 PD-L1 Inhibitors Industry Opportunities and Challenges
- 2.4 PD-L1 Inhibitors Industry Restraints
3 PD-L1 Inhibitors Market by Company
- 3.1 Global PD-L1 Inhibitors Company Revenue Ranking in 2025
- 3.2 Global PD-L1 Inhibitors Revenue by Company (2021-2026)
- 3.3 Global PD-L1 Inhibitors Sales Volume by Company (2021-2026)
- 3.4 Global PD-L1 Inhibitors Average Price by Company (2021-2026)
- 3.5 Global PD-L1 Inhibitors Company Ranking (2024-2026)
- 3.6 Global PD-L1 Inhibitors Company Manufacturing Base and Headquarters
- 3.7 Global PD-L1 Inhibitors Company Product Type and Application
- 3.8 Global PD-L1 Inhibitors Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global PD-L1 Inhibitors Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 PD-L1 Inhibitors Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 PD-L1 Inhibitors Market by Type
- 4.1 PD-L1 Inhibitors Type Introduction
- 4.1.1 TECENTRIQ
- 4.1.2 Imfinzi
- 4.1.3 Bavencio
- 4.2 Global PD-L1 Inhibitors Sales Volume by Type
- 4.2.1 Global PD-L1 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global PD-L1 Inhibitors Sales Volume by Type (2021-2032)
- 4.2.3 Global PD-L1 Inhibitors Sales Volume Share by Type (2021-2032)
- 4.3 Global PD-L1 Inhibitors Sales Value by Type
- 4.3.1 Global PD-L1 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global PD-L1 Inhibitors Sales Value by Type (2021-2032)
- 4.3.3 Global PD-L1 Inhibitors Sales Value Share by Type (2021-2032)
5 PD-L1 Inhibitors Market by Application
- 5.1 PD-L1 Inhibitors Application Introduction
- 5.1.1 Retail Pharmacy
- 5.1.2 Hospital Pharmacy
- 5.1.3 Other
- 5.2 Global PD-L1 Inhibitors Sales Volume by Application
- 5.2.1 Global PD-L1 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global PD-L1 Inhibitors Sales Volume by Application (2021-2032)
- 5.2.3 Global PD-L1 Inhibitors Sales Volume Share by Application (2021-2032)
- 5.3 Global PD-L1 Inhibitors Sales Value by Application
- 5.3.1 Global PD-L1 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global PD-L1 Inhibitors Sales Value by Application (2021-2032)
- 5.3.3 Global PD-L1 Inhibitors Sales Value Share by Application (2021-2032)
6 PD-L1 Inhibitors Regional Sales and Value Analysis
- 6.1 Global PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global PD-L1 Inhibitors Sales by Region (2021-2032)
- 6.2.1 Global PD-L1 Inhibitors Sales by Region: 2021-2026
- 6.2.2 Global PD-L1 Inhibitors Sales by Region (2027-2032)
- 6.3 Global PD-L1 Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global PD-L1 Inhibitors Sales Value by Region (2021-2032)
- 6.4.1 Global PD-L1 Inhibitors Sales Value by Region: 2021-2026
- 6.4.2 Global PD-L1 Inhibitors Sales Value by Region (2027-2032)
- 6.5 Global PD-L1 Inhibitors Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America PD-L1 Inhibitors Sales Value (2021-2032)
- 6.6.2 North America PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe PD-L1 Inhibitors Sales Value (2021-2032)
- 6.7.2 Europe PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific PD-L1 Inhibitors Sales Value (2021-2032)
- 6.8.2 Asia-Pacific PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America PD-L1 Inhibitors Sales Value (2021-2032)
- 6.9.2 South America PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa PD-L1 Inhibitors Sales Value (2021-2032)
- 6.10.2 Middle East & Africa PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
7 PD-L1 Inhibitors Country-level Sales and Value Analysis
- 7.1 Global PD-L1 Inhibitors Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global PD-L1 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global PD-L1 Inhibitors Sales by Country (2021-2032)
- 7.3.1 Global PD-L1 Inhibitors Sales by Country (2021-2026)
- 7.3.2 Global PD-L1 Inhibitors Sales by Country (2027-2032)
- 7.4 Global PD-L1 Inhibitors Sales Value by Country (2021-2032)
- 7.4.1 Global PD-L1 Inhibitors Sales Value by Country (2021-2026)
- 7.4.2 Global PD-L1 Inhibitors Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.5.2 USA PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.9.2 France PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.16.2 China PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.19.2 India PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Merck KGaA
- 8.1.1 Merck KGaA Company Information
- 8.1.2 Merck KGaA Business Overview
- 8.1.3 Merck KGaA PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Merck KGaA PD-L1 Inhibitors Product Portfolio
- 8.1.5 Merck KGaA Recent Developments
- 8.2 Roche
- 8.2.1 Roche Company Information
- 8.2.2 Roche Business Overview
- 8.2.3 Roche PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Roche PD-L1 Inhibitors Product Portfolio
- 8.2.5 Roche Recent Developments
- 8.3 AstraZeneca
- 8.3.1 AstraZeneca Company Information
- 8.3.2 AstraZeneca Business Overview
- 8.3.3 AstraZeneca PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
- 8.3.4 AstraZeneca PD-L1 Inhibitors Product Portfolio
- 8.3.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 PD-L1 Inhibitors Value Chain Analysis
- 9.1.1 PD-L1 Inhibitors Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 PD-L1 Inhibitors Sales Mode & Process
- 9.2 PD-L1 Inhibitors Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 PD-L1 Inhibitors Distributors
- 9.2.3 PD-L1 Inhibitors Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst